Literature DB >> 25153967

Carbapenem-resistant Enterobacter cloacae isolates producing KPC-3, North Dakota, USA.

Lee M Kiedrowski, Dubert M Guerrero, Federico Perez, Roberto A Viau, Laura J Rojas, Maria F Mojica, Susan D Rudin, Andrea M Hujer, Steven H Marshall, Robert A Bonomo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25153967      PMCID: PMC4178402          DOI: 10.3201/eid2009.140344

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Carbapenem-resistant Enterobacteriaceae (CRE) continue to emerge as a serious public health threat throughout the world (). CRE infections in the United States are often mediated by acquisition of Klebsiella pneumoniae carbapenemase (KPC) expressed by Klebsiella spp., although KPC is also found in other genera (). The spread of KPC-producing, gram-negative bacteria in hospitals has been linked to severity of illness, co-existing medical conditions, exposure to antimicrobial drugs, and need for chronic care (). After reporting of CRE infections to the North Dakota Department of Health became mandatory in 2011, a total of 20 CRE cases were noted in 12 of 53 counties (2.9 cases/100,000 population []). Most cases involved infection with Enterobacter cloacae and occurred in Cass County, where the state’s largest city, Fargo, is located. We describe an outbreak of clonal carbapenem-resistant E. cloacae in a health care system in Fargo. Sanford Health is a 583-bed, acute-care facility, representing ≈70% of acute-care beds in Fargo. The hospital handles >27,000 admissions/year and serves as a referral center for a large area of the state, and the only long-term acute-care (LTAC) facility in the eastern half of the state operates on its campus. During December 2011–December 2012, all isolates of Enterobacteriaceae with reduced susceptibility to ertapenem (MIC ≥1 µg/mL) identified at the hospital’s clinical microbiology laboratory were screened for carbapenemase production by using the modified Hodge test (mHT), according to Clinical and Laboratory Standards Institute recommendations (). Identification and susceptibility testing were done with the MicroScan system (Siemens Healthcare Diagnostics, Tarrytown, NY, USA); MICs of carbapenems were confirmed with Etest (bioMérieux, Durham, NC, USA). Three carbapenem-resistant E. cloacae isolates from documented cases of CRE infection at the hospital during 2010 were analyzed for comparison. To characterize carbapenem-resistant and mHT-positive isolates, we used PCR to amplify and sequence the carbapenemase genes blaIMP, blaNDM, blaVIM, and blaKPC by using established methods (). The upstream sequence of blaKPC-positive strains was analyzed to determine the isoform of the transposon Tn4401 that harbored blaKPC (). We investigated genetic similarity among isolates by repetitive sequence-based PCR; isolates with >95% similarity were considered clonal (). We also sequenced the highly conserved hsp60 gene () and attempted conjugative transfer of the blaKPC gene by growing KPC-producing E. cloacae along with sodium azide–resistant Escherichia coli J-53. As part of the study, we examined records of patients from whom carbapenem-resistant E. cloacae was isolated. The study was approved by the Institutional Review Board at Sanford Health. During December 2011–December 2012, a total of 19 single-patient E. cloacae isolates and 1 E. aerogenes isolate had positive mHT results. blaKPC was detected in 17 of the 19 E. cloacae isolates and in the 3 carbapenem-resistant E. cloacae isolates from 2010. For all 20 of those isolates, sequencing revealed blaKPC-3 in association with isoform d of the transposon Tn4401, and all isolates were clonally related (Figure). All 20 isolates also had an identical hsp60 sequence belonging to cluster VI in the Hoffman and Roggenkamp scheme (). Conjugation of a blaKPC-containing plasmid into E. coli J-53 was successful for 1 strain.
Figure

Genetic typing of carbapenem-resistant Enterobacter cloacae identified from patients at Sanford Health in Fargo, North Dakota, USA. Repetitive sequence–based PCR was used. The dendrogram at left displays the percentage similarity among band patterns shown at right. Isolate numbers ND 1, ND 4–5, ND 7–14, and ND 18–23 indicate Klebsiella pneumoniae carbapenemase (KPC) 3–producing E. cloacae isolates isolated during December 2011–December 2012; ND A–C indicate KPC-3–producing E. cloacae isolated during 2010. All KPC-3–producing E. cloacae isolates share >97% similarity, indicating a clonal strain. ND 15 and 16 are E. cloacae, and ND 17 is E. aerogenes, genetically distinct and without carbapenemases.

Genetic typing of carbapenem-resistant Enterobacter cloacae identified from patients at Sanford Health in Fargo, North Dakota, USA. Repetitive sequence–based PCR was used. The dendrogram at left displays the percentage similarity among band patterns shown at right. Isolate numbers ND 1, ND 4–5, ND 7–14, and ND 18–23 indicate Klebsiella pneumoniae carbapenemase (KPC) 3–producing E. cloacae isolates isolated during December 2011–December 2012; ND A–C indicate KPC-3–producing E. cloacae isolated during 2010. All KPC-3–producing E. cloacae isolates share >97% similarity, indicating a clonal strain. ND 15 and 16 are E. cloacae, and ND 17 is E. aerogenes, genetically distinct and without carbapenemases. All 20 of the patients from whom KPC-producing CRE isolates were obtained (17 from this study, 3 from 2010) had been hospitalized at Sanford Health during the 3 months before CRE isolation; 13 (65%) were admitted to intensive care. In addition, 13 (65%) patients had been admitted to the LTAC during the year before CRE isolation. Co-colonization with multidrug-resistant bacteria was documented in 16 (80%) patients, including extended-spectrum β-lactamase–producing and carbapenem-resistant organisms in 4 and 2 patients, respectively. Seven (35%) patients died; 3 (15%) deaths were attributed to CRE infection. One of the patients was a neonate 30 days of age. The finding of KPC-3–producing E. cloacae in North Dakota contrasts with the predominant epidemiology of CRE across the United States. Most CRE cases nationwide are caused by KPC-producing K. pneumoniae (). KPC-type β-lactamases were previously identified in diverse strains of Enterobacter spp. from an urban health care system in Detroit, accounting for ≈15% of CRE (). In contrast, our genetic analysis reveals a uniform genetic background among KPC-producing E. cloacae, which suggests horizontal dissemination of an outbreak strain. Because active surveillance programs do not exist at our facility, this study probably underestimates the extent of CRE spread. We found that patients with KPC-producing E. cloacae in this sample were exposed to an LTAC and concomitantly were colonized or infected with other multidrug-resistant organisms (). Although the spatio-temporal origin of the outbreak (acute care vs. LTAC) remains undefined, these findings likely reflect longer exposure to the continuum of care and higher rates of co-existing conditions within the LTAC population. This outbreak of KPC-producing E. cloacae infections in a health care system in North Dakota highlights the infection control challenges of long-term care facilities and the potential role they play in CRE dissemination.
  7 in total

1.  Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity.

Authors:  Mahesh Swaminathan; Saarika Sharma; Stephanie Poliansky Blash; Gopi Patel; David B Banach; Michael Phillips; Vincent LaBombardi; Karen F Anderson; Brandon Kitchel; Arjun Srinivasan; David P Calfee
Journal:  Infect Control Hosp Epidemiol       Date:  2013-06-11       Impact factor: 3.254

2.  Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center.

Authors:  Dror Marchaim; Teena Chopra; Federico Perez; Kayoko Hayakawa; Paul R Lephart; Suchitha Bheemreddy; Christopher Blunden; Andrea M Hujer; Susan Rudin; Maryann Shango; Michelle Campbell; Jastin Varkey; Jessica Slim; Farah Ahmad; Diixa Patel; Ting-Yi Chen; Jason M Pogue; Hossein Salimnia; Sorabh Dhar; Robert A Bonomo; Keith S Kaye
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09       Impact factor: 3.254

3.  Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination.

Authors:  Federico Perez; Andrea Endimiani; Amy J Ray; Brooke K Decker; Christopher J Wallace; Kristine M Hujer; David J Ecker; Mark D Adams; Philip Toltzis; Michael J Dul; Anne Windau; Saralee Bajaksouzian; Michael R Jacobs; Robert A Salata; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2010-05-31       Impact factor: 5.790

Review 4.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

5.  Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258.

Authors:  Brandon Kitchel; J Kamile Rasheed; Jean B Patel; Arjun Srinivasan; Shiri Navon-Venezia; Yehuda Carmeli; Alma Brolund; Christian G Giske
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

6.  Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.

Authors:  Thierry Naas; Gaelle Cuzon; Maria-Virginia Villegas; Marie-Frédérique Lartigue; John P Quinn; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

7.  Population genetics of the nomenspecies Enterobacter cloacae.

Authors:  Harald Hoffmann; Andreas Roggenkamp
Journal:  Appl Environ Microbiol       Date:  2003-09       Impact factor: 4.792

  7 in total
  14 in total

Review 1.  Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007-14.

Authors:  Angela Gomez-Simmonds; Yue Hu; Sean B Sullivan; Zheng Wang; Susan Whittier; Anne-Catrin Uhlemann
Journal:  J Antimicrob Chemother       Date:  2016-04-26       Impact factor: 5.790

2.  Clonal Dissemination of Enterobacter cloacae Harboring blaKPC-3 in the Upper Midwestern United States.

Authors:  Melissa L Hargreaves; Kristin M Shaw; Ginette Dobbins; Paula M Snippes Vagnone; Jane E Harper; Dave Boxrud; Ruth Lynfield; Maliha Aziz; Lance B Price; Kevin A T Silverstein; Jessica L Danzeisen; Bonnie Youmans; Kyle Case; Srinand Sreevatsan; Timothy J Johnson
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

3.  The Prevalence and Molecular Epidemiology of Multidrug-Resistant Enterobacteriaceae Colonization in a Pediatric Intensive Care Unit.

Authors:  Nuntra Suwantarat; Latania K Logan; Karen C Carroll; Robert A Bonomo; Patricia J Simner; Susan D Rudin; Aaron M Milstone; Tsigereda Tekle; Tracy Ross; Pranita D Tamma
Journal:  Infect Control Hosp Epidemiol       Date:  2016-02-09       Impact factor: 3.254

4.  A Prolonged Outbreak of KPC-3-Producing Enterobacter cloacae and Klebsiella pneumoniae Driven by Multiple Mechanisms of Resistance Transmission at a Large Academic Burn Center.

Authors:  Hajime Kanamori; Christian M Parobek; Jonathan J Juliano; David van Duin; Bruce A Cairns; David J Weber; William A Rutala
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae.

Authors:  Johanne Blais; Sara Lopez; Cindy Li; Alexey Ruzin; Srijan Ranjitkar; Charles R Dean; Jennifer A Leeds; Anthony Casarez; Robert L Simmons; Folkert Reck
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 6.  Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?

Authors:  Federico Perez; Nadim G El Chakhtoura; Krisztina M Papp-Wallace; Brigid M Wilson; Robert A Bonomo
Journal:  Expert Opin Pharmacother       Date:  2016-03-09       Impact factor: 3.889

7.  Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: Shifting burden of disease?

Authors:  Nicholas S Britt; David J Ritchie; Marin H Kollef; Carey-Ann D Burnham; Michael J Durkin; Nicholas B Hampton; Scott T Micek
Journal:  Am J Infect Control       Date:  2018-04-26       Impact factor: 2.918

8.  Carbapenem-Resistant Enterobacter cloacae in Patients from the US Veterans Health Administration, 2006-2015.

Authors:  Brigid M Wilson; Nadim G El Chakhtoura; Sachin Patel; Elie Saade; Curtis J Donskey; Robert A Bonomo; Federico Perez
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

9.  Genomic and Geographic Context for the Evolution of High-Risk Carbapenem-Resistant Enterobacter cloacae Complex Clones ST171 and ST78.

Authors:  Angela Gomez-Simmonds; Medini K Annavajhala; Zheng Wang; Nenad Macesic; Yue Hu; Marla J Giddins; Aidan O'Malley; Nora C Toussaint; Susan Whittier; Victor J Torres; Anne-Catrin Uhlemann
Journal:  mBio       Date:  2018-05-29       Impact factor: 7.867

10.  Comprehensive Genome Analysis of Carbapenemase-Producing Enterobacter spp.: New Insights into Phylogeny, Population Structure, and Resistance Mechanisms.

Authors:  Kalyan D Chavda; Liang Chen; Derrick E Fouts; Granger Sutton; Lauren Brinkac; Stephen G Jenkins; Robert A Bonomo; Mark D Adams; Barry N Kreiswirth
Journal:  MBio       Date:  2016-12-13       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.